We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. The pre-analytical phase of laboratory medicine
- Prof. Giuseppe Lippi
-
2. Fundamentals of complete blood count analysis- Prof. Roberta Rolla
-
3. Laboratory assessment of coagulation- Prof. Gian Luca Salvagno
-
4. Oncological biomarkers
- Prof. Dr. Tomris Ozben
-
5. Liquid biopsy
- Dr. Fabio Del Ben
-
6. Clinical biochemistry: introduction
- Dr. Anna Carobene
Printable Handouts
Navigable Slide Index
- Introduction
- What is liquid biopsy?
- Key biomarkers
- Benefit comparison
- Benefit comparison: invasiveness and repeatability
- Clinical applications in oncology
- Benefit comparison: monitoring and tumor heterogeneity
- Intratumoral heterogeneity
- Benefit comparison: amount of tumor material
- Circulating tumor DNA (ctDNA)
- cfDNA: quantitative aspects
- FDA/CE-IVD approved ctDNA assays
- Indications of NGS panels
- DNA extraction
- DNA extraction: silica columns
- DNA extraction: magnetic beads
- Silica columns vs. magnetic beads
- Analysis of sequences
- Warnings: false negatives
- Warnings: false positives
- Clonal hematopoiesis
- Circulating Tumor Cells (CTC)
- Most extensively studied CTC population
- CTC: quantitative aspects
- A note on quantitative aspects
- Process of CTC detection
- Process of CTC detection: blood draw
- Process of CTC detection: enrichment
- Process of CTC detection: enumeration
- Process of CTC detection: isolation
- Process of CTC detection: molecular analysis
- Research and development (R&D) applications
- FDA clearance
- Intended use of FDA-approved devices
- Parsortix: how it works?
- CellSearch: how it works?
- Functional methods: secreted molecules
- Functional methods: abnormal metabolism
- Clinical validation
- CTC in non-metastatic settings
- Non-oncological applications
- Conclusion
- Financial disclosures
Topics Covered
- Targets of liquid biopsy
- Benefits of liquid biopsy
- Circulating tumor DNA -Circulating Tumor Cells (CTCs)
- Process of CTC detection
- Advances in cancer detection
- FDA status of liquid biopsy based methods for cancer detection
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Del Ben, F. (2026, February 26). Liquid biopsy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2026, from https://doi.org/10.69645/OCPE3101.Export Citation (RIS)
Publication History
- Published on February 26, 2026
Financial Disclosures
- Co-founder and shareholder of Lighthouse Biotech, a start-up focused on cell-based liquid biopsy. Co-inventor of patents (WO2022009242A1 and WO2015092726A1) involving CTC-based liquid biopsy.
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...
0:00
I am Fabio Del Ben.
I'm a clinical
pathologist in Italy,
at the CRO Aviano IRCCS
National Cancer Institute.
I will talk to you
about liquid biopsy,
especially in
oncological settings.
0:18
So, what is liquid biopsy?
For liquid biopsy, it's meant
a non-invasive
diagnostic technique
analyzing tumor
material in blood.
Please note that the targets
of liquid biopsy are not
the traditional serum biomarkers
like CA125, CEA or CA19-9.
These are serum biomarkers
which have been used
for several years.
But liquid biopsy is
another kind of
technology and analysis.
0:54
The targets of liquid
biopsies can be different
starting from
circulating tumor DNA
to circulating tumor cells,
exosomes, which are fragments,
extracellular vesicles
detaching from cells,
or even cell-free RNA.
The best knowledge and the
most widely available tools
are about circulating tumor DNA,
which is considered the
most advanced application
in liquid biopsy
immediately followed
by circulating tumor cells.
1:28
But why is liquid biopsy useful?
Which benefits add to the
usual core needle biopsy
which is performed
in cancer settings?
1:40
First of all, liquid biopsy
has minimal invasiveness
because it can be
obtained by a simple
venous blood draw
like glucose testing,
for example.
We are talking about
a simple blood draw
from the arm, while
core needle biopsy is
a very strongly
invasive procedure,
punching the core of the
tumor with a thick needle
and it cannot be done
in particular locations
such as the brain or a
highly vascularized organ
that is much more difficult to
obtain a core needle biopsy.
For the same reason,
the repeatability
of liquid biopsy is high
while the repeatability
of core needle
biopsy is limited.